Novartis (NOVN) Stock: AI & NFL Impact for Investors

• At the World Economic Forum 2026 in Davos, Dr. Giovanni Caforio, President of Novartis, announced an earlier AI and data-driven national partnership with the Brunei Ministry of Health and EVYD Technology to prevent cardiovascular disease, while Novartis also unveiled a prostate cancer awareness campaign with the NFL based on a Super Bowl commercial titled “Relax, it’s a blood test.”
• These initiatives position Novartis as an innovative healthcare company that uses rich data, artificial intelligence and public awareness campaigns to advance early detection and prevention of the most important non-communicable diseases.
• We will now examine how Novartis’ AI-powered cardiovascular program in Brunei shapes Novartis’ broader investment narrative around data-driven innovation in healthcare.

Find companies with promising cash flow potential that are trading below their fair value.

What is Novartis’ investment concept?

Novartis is a large, diversified pharmaceutical company that combines a long history of rising dividends and solid profitability with a push into data-driven healthcare – a big picture worth investing in. Brunei’s cardiovascular disease AI program and the NFL’s prostate cancer awareness campaign support this picture, but they are more about brand, partnerships and proof of concept than short-term financial impact. In the near term, the key catalysts remain the upcoming earnings on February 4, the ramp-up of recently approved therapies, and how the market interprets the fact that Novartis is trading below the sector’s valuation multiples despite a strong multi-year total return. On the risk side, the new announcements do not change the existing focus on implementation, pricing pressure and relatively high debt; if anything, they slightly increase expectations that AI-powered programs can translate into future value. However, one particular risk could surprise investors if they overlook it.

Despite the decline, Novartis shares could still be trading above their fair value and there could still be some more downside potential. Find out how much.

Exploring other perspectives

The five Simply Wall St. Community valuations range from about $105 to about $254 and reflect very different return expectations. With this in mind, recent initiatives in artificial intelligence and public health raise questions about the level of execution risk and how effectively these investments support Novartis’ core revenue engine over time.

Discover 5 more Novartis fair value estimates – why the stock could be worth more than twice its current price!

Create your own Novartis narrative

Do you disagree with this assessment? Create your own report in under 3 minutes – exceptional investment returns rarely come from following the herd.

• A great place to start your Novartis research is our analysis, where we highlight 5 key benefits and 1 key warning sign that could influence your investment decision.
• Our free Novartis Research report provides comprehensive fundamental analysis summarized in a single graphic – the snowflake – making it easier for you to assess Novartis’ overall financial position at a glance.

Are you considering other strategies?

Now might be the best time to get started. These stocks are freshly selected from our daily scans. Don’t hesitate:

This article from Simply Wall St is general in nature. We comment solely based on historical data and analyst forecasts, using an unbiased methodology. It does not constitute a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to provide you with long-term, fundamental-based analysis. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Are you worried about the content? Contact us directly. Alternatively, you can also send an email to [email protected].